42 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
Selcia
Thioxylated cyclosporin A for studying protein-drug interactions.
Technical University Dresden
From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
Novartis Institutes For Biomedical Research
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Novartis Institutes For Biomedical Research
Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
Max Planck Research Unit For Enzymology of Protein Folding
Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
Scynexis
Simultaneous identification of multiple receptors of natural product using an optimized cDNA phage display cloning.
Chinese Academy of Sciences
Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives.
Guilford Pharmaceuticals
Structure-activity studies of ground- and transition-state analogue inhibitors of cyclophilin.
Southern Methodist University
Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs.
Departement D'Ingenierie Et D'Etudes Des Proteines
Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.
Centre De Recherche De Paris
Oligopeptide cyclophilin inhibitors: a reassessment.
Max Planck Research Unit For Enzymology of Protein Folding
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
Southern Research Institute
Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.
TBA
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
Scynexis
Augmented photoswitching modulates immune signaling.
Max Planck Research Unit For Enzymology of Protein Folding
Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
East China University of Science and Technology
Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
Peking University
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
Gwangju Institute of Science and Technology (Gist)
Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A.
University of Montpellier
Design, Optimization, and Structural Characterization of an Apoptosis-Inducing Factor Peptide Targeting Human Cyclophilin A to Inhibit Apoptosis Inducing Factor-Mediated Cell Death.
University of Campania "L. Vanvitelli
SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
Chonnam National University
Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A.
Chinese Academy of Sciences
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)
Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
Chonnam National University
Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
Chonnam National University
Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
East China University of Science and Technology
Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain.
Sandoz Pharma
The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
Sandoz Pharma
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
Gilead Sciences
Characterization of MymA protein as a flavin-containing monooxygenase and as a target of isoniazid.
Miranda House